PART I Overview We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies. Our strategy is to identify immune-mediated diseases in which translational and c...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001104659-26-032080 | EDGAR | 96K words |
| 2025-03-25 | 2024-12-31 | 0001410578-25-000443 | EDGAR | 98K words |
| 2024-03-28 | 2023-12-31 | 0001410578-24-000329 | EDGAR | 101K words |
| 2023-03-28 | 2022-12-31 | 0001410578-23-000374 | EDGAR | — |
| 2022-04-11 | 2021-12-31 | 0001410578-22-000860 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001855644-26-000006 | EDGAR | 19K words |
| 2025-11-13 | 2025-09-30 | 0001104659-25-110793 | EDGAR | 36K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001783 | EDGAR | 32K words |
| 2025-05-08 | 2025-03-31 | 0001410578-25-001100 | EDGAR | 25K words |
| 2024-11-07 | 2024-09-30 | 0001410578-24-001779 | EDGAR | 30K words |
| 2024-08-13 | 2024-06-30 | 0001410578-24-001371 | EDGAR | 28K words |
| 2024-05-09 | 2024-03-31 | 0001410578-24-000655 | EDGAR | 23K words |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002337 | EDGAR | 28K words |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001829 | EDGAR | 27K words |
| 2023-05-12 | 2023-03-31 | 0001410578-23-001121 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003377 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001410578-22-002385 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-17 | 0001104659-26-097526 | EDGAR | 8K words |
| 2026-08-11 | 0001855644-26-000007 | EDGAR | 2K words |
| 2026-03-19 | 0001104659-26-032077 | EDGAR | 6K words |
| 2026-03-10 | 0001104659-26-025520 | EDGAR | 6K words |
| 2026-03-05 | 0001104659-26-023806 | EDGAR | 1K words |
| 2026-02-26 | 0001104659-26-019827 | EDGAR | 1K words |
| 2026-02-23 | 0001104659-26-018312 | EDGAR | 1K words |
| 2026-02-11 | 0001104659-26-012935 | EDGAR | 6K words |
| 2026-01-26 | 0001104659-26-006326 | EDGAR | 1K words |
| 2026-01-12 | 0001104659-26-002688 | EDGAR | 6K words |
137 total filings indexed. 110 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001855644 |
| Ticker | ZURA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | E9 |
| Website | https://www.zurabio.com |
| Listed | 2023-03-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ZURA (~200 tokens, structured JSON with cryptographic provenance)